GleamWall
中文EN

XERS Xeris Biopharma Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1867096 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY38.4%
TTM net income YoY58.5%
TTM EPS YoY70.0%
Revenue 3-yr CAGR34.1%
Net income 3-yr CAGR—

Margins

Gross margin87.4%
Operating margin12.7%
Net margin-1.8%
FCF margin—
EBITDA margin13.1%

Returns

ROE-27.1%
ROA-1.6%
ROIC (approx.)31.5%
Asset turnover0.93x

Leverage & solvency

Liabilities / assets88.5%
Debt / equity3.89x
Current ratio2.15x
Interest coverage1.70x

Cash quality & payout

Operating cash flow / net income-11.34x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$107.22M$92.10M$83.13M$85.81M$74.38M$71.54M$60.12M$60.10M
Cost of revenue$12.43M$12.51M$10.57M$10.95M$11.00M$11.90M$8.73M$9.48M
Gross profit$94.80M$79.59M$72.55M$74.86M$63.38M$59.64M$51.39M$50.62M
R&D expense$11.06M$10.67M$8.78M$7.87M$7.48M$8.05M$7.75M$6.09M
SG&A expense$64.11M$61.03M$53.14M$47.50M$46.46M$44.39M$44.02M$40.14M
Operating income$16.92M$5.17M$7.92M$16.77M$6.73M$4.48M-$3.09M$1.68M
Interest expense$6.46M$6.95M$6.88M$7.15M$7.27M$7.36M$7.30M$7.70M
Income tax$0$0$0$0$0$0$0$0
Net income$11.29M-$31.10M$2.23M$11.08M$621,000-$1.93M-$9.22M-$5.11M
EBITDA$17.22M$5.50M$8.25M$17.11M$7.03M$4.81M-$2.77M$1.99M
EPS (basic)0.06-0.180.01—0.00-0.01-0.06—
EPS (diluted)0.06-0.180.01—0.00-0.01-0.06—
Weighted avg. shares (diluted)189.92M172.82M177.63M—177.62M159.46M152.45M—
Balance sheet
Cash & equivalents$131.08M$121.75M$111.75M$111.04M$91.60M$59.28M$58.44M$75.74M
Short-term investments———————$0
Receivables$68.60M$58.10M$56.30M$51.05M$53.75M$53.05M$46.33M$40.41M
Inventory$76.92M$80.93M$74.23M$68.67M$67.46M$67.28M$52.69M$48.17M
Current assets$289.26M$274.76M$251.68M$240.31M$224.02M$185.58M$163.49M$167.66M
PP&E, net$4.64M$4.83M$5.03M$4.95M$4.95M$5.28M$5.26M$5.56M
Goodwill$22.86M$22.86M$22.86M$22.86M$22.86M$22.86M$22.86M$22.86M
Intangibles$79.95M$82.66M$85.37M$88.08M$90.79M$93.50M$96.21M$98.92M
Total assets$423.22M$411.90M$392.01M$383.53M$370.19M$334.69M$315.45M$323.06M
Current liabilities$134.48M$189.57M$118.59M$109.57M$116.20M$95.17M$95.07M$100.44M
Short-term debt—$63.78M—$0$0$0$11.96M$15.10M
Long-term debt$189.71M$188.81M$221.22M$220.34M$219.47M$218.63M$217.81M$217.01M
Total debt$189.71M$252.59M$221.22M$220.34M$219.47M$218.63M$229.76M$232.11M
Total liabilities$374.44M$421.64M$379.00M$369.84M$371.05M$353.99M$350.58M$352.68M
Shareholders' equity$48.78M-$9.73M$13.01M$13.69M-$861,000-$19.30M-$35.13M-$29.61M
Net debt$58.63M$130.84M$109.47M$109.29M$127.87M$159.34M$171.32M$156.36M
Shares outstanding182.57M173.59M172.56M166.22M165.53M161.22M156.01M149.43M
Cash flow statement
Operating cash flow$35.47M$8.26M$9.87M$20.04M$18.43M$182,000-$10.03M$1.98M
Investing cash flow-$159,000-$209,000-$325,000-$333,000-$71,000-$279,000-$13,000$10.02M
Financing cash flow-$25.98M$1.94M-$8.84M-$266,000$13.85M$942,000-$3.14M$398,000
Depreciation & amortization$300,000$323,000$337,000$335,000$300,000$325,000$315,000$313,000
Stock-based compensation$10.80M$11.07M$4.14M$5.27M$7.64M$5.01M$4.44M$3.60M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.